HpVac

<!-- Name:DistributionId Value:1000800325 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:5555 -->…

- Significant expansion of allergy research expertise Geneva, Switzerland, November 23, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and inflammatory diseases, today…

- Major milestone for accelerating the development of HpVac-13 in allergic diseases Geneva, Switzerland, October 18, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and…